$CTXR News Article - Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma https://marketwirenews.com/news-releases/citi...59614.html
(0)
(0)
Citius Pharmaceuticals Inc. (CTXR) Stock Research Links